Fluad's Italian Problem Could Reduce Confidence In Vaccines Across Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
The EMA has given Novartis’ flu vaccine Fluad the all-clear after serious safety concerns were raised in Italy, but the publicity around the drug could pressure an already burdened vaccines industry.
You may also be interested in...
France Suspends Bayer Diane 35: Post-Mediator Strictness Or Prelude To Broad Withdrawal?
France has announced the suspension of Bayer’s acne drug, which is widely used as a contraceptive, after confirming its role in the death of four patients; a subsequent referral to the EMA could herald a Europe-wide suspension.
Novartis Flu Vaccine Problems Highlight Lack Of European Co-ordination
Quality issues that have seen two Novartis influenza vaccines suspended in a number of European countries have highlighted the shortfalls of a co-ordinated European approach to such problems.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.